Opendata, web and dolomites

ANTHEM SIGNED

ANTHEM: A Novel Tolerogenic vaccine for the treatment of antibodies in HaEMophilia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ANTHEM project word cloud

Explore the words cloud of the ANTHEM project. It provides you a very rough idea of what is the project "ANTHEM" about.

counteract    reactions    commercialisation    technologies    date    realize    constitute    validate    iti    blood    create    care    viii    tolerance    heavy    transferred    accelerated    adverse    clinical    patients    lies    strategic    vulnerable    tolerogenic    efficacy    failed    exerts    mortality    therapy    mean    trial    protein    immune    basis    uses    crippling    haemophilia    safe    dendritic    body    annual    healthcare    health    standard    budgets    vaccine    serious    na    back    35    pressing    data    reaching    haematologists    3012    arthropathy    overcome    clotting    person    mechanism    situation    utilizes    morbidities    117    consequence    cells    emphasise    eur    kols    resistance    patient    million    burden    outside    performed    substantially    capacity    treat    induction    leads    supports    establishing    prevalence    preliminary    neutralizing    reprogrammed    antibodies    platform    cornerstone    strategy    eradicate    safety    treatment    lifetime    idogen    policy    humans   

Project "ANTHEM" data sheet

The following table provides information about the project.

Coordinator
IDOGEN AB 

Organization address
address: SCHEELEVAGEN 2
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://idogen.com
 Total cost 2˙868˙734 €
 EC max contribution 2˙868˙734 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDOGEN AB SE (LUND) coordinator 2˙868˙734.00

Map

 Project objective

This project will develop and validate IN-3012, a novel tolerogenic vaccine that utilizes a person’s own cells to treat neutralizing antibodies (NA) in Haemophilia A patients who have failed immune tolerance induction (ITI). Haemophilia A patients are given the blood clotting protein, factor VIII as standard of care. However, a serious consequence is the development of NA towards factor VIII leading to therapy resistance. This leads to crippling arthropathy, other morbidities and high mortality. ITI is the most used treatment of this condition but 35% of patients do not respond and are in a vulnerable situation.

Haematologists and KOLs emphasise the pressing need for safe and effective technologies to overcome NA in Haemophilia A, which is not possible today. The estimated mean annual cost of a Haemophilia patient in Europe is over EUR 117,000 EUR with the mean lifetime cost reaching EUR 7.8 million. This is substantially higher in patients who have failed ITI. Therefore, while this condition has low prevalence, it exerts heavy burden on healthcare budgets and is thus a top EU health policy priority.

Idogen’s technology platform allows cells from the patient’s blood to be reprogrammed outside the body to dendritic cells with the capacity to specifically counteract adverse immune reactions. The reprogrammed cells are transferred back to the patient. IN-3012 uses this mechanism to create tolerance to factor VIII.

The research performed to date strongly supports the vaccine’s potential to eradicate NA. The proposed project will bring IN-3012 through a Phase I/II clinical trial in humans. The safety and preliminary efficacy data will constitute the basis for further clinical development and commercialisation of the product. Idogen’s strategic focus lies in establishing IN-3012 as a novel treatment in Haemophilia A patients having failed ITI. This will constitute the cornerstone of Idogen’s accelerated growth. This project is the key step to realize the strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More